Clinical Trial Dosing Range tested: Doses from 0.3 mg up to 4.5 mg weekly have been investigated
17,173,184,190 The prognosis for DRPN is generally favorable, with many patients experiencing significant recovery over months to years, although some may have residual weakness, particularly with early diagnosis and appropriate management
Mounjaro (SURMOUNT Trials) The SURMOUNT clinical program highlighted the superior potency of Tirzepatide
Dihydroberberine, a hydrogenated derivative of berberine firstly identified in Phellodendri Chinese cortex, exerts anti-inflammatory effect via dual modulation of NF-B and MAPK signaling pathways
The increases were broadly consistent with those documented for approved GLP-1 receptor agonists in their respective SmPCs
Unlike other programs, we offer 1-on-1 virtual consultations every month with our registered dietitians to ensure you receive tailored dietary advice and guidance throughout your journey